• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Shionogi & Co.

Xocova: Powerful New Japanese Pill for Coronavirus Treatment
Posted inCOVID-19, Infections, New Drugs, Regulatory

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

November 27, 2022December 5, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

Paxlovid (nirmatrelvir + ritonavir)
Posted inCOVID-19, Infections, Regulatory

Paxlovid for COVID-19 Treatment. All Details

August 24, 2022November 28, 2022

Paxlovid: treatment efficacy, “Paxlovid mouth”, COVID-19 rebound, management of Omicron variant, treatment resistance, generics, mechanism of action, price.

olorofim
Posted inClinical Trials, Infections, Rare/Orphan Diseases

Olorofim: New Antifungal Drug

June 9, 2022September 8, 2022

Olorophim by F2G and Shionogi & Co. is focused on invasive aspergillosis treatment.

Redasemtide: Universal Medicine for Regeneration of Any Tissue
Posted inClinical Trials, Metabolism, Neuroscience, Rare/Orphan Diseases

Redasemtide: Universal Medicine for Regeneration of Any Tissue

February 12, 2022September 8, 2022

Redasemtide as a lifesaver for the most devastating diseases, including stroke, osteoarthritis, cardiomyopathy, and bullous epidermolysis.

cough
Posted inNeuroscience, New Drugs, Regulatory

Lyfnua: First Drug for Refractory or Unexplained Chronic Cough

January 25, 2022September 8, 2022

Gefapixant will reduce cough frequency, thereby improving patients’ quality of life.

Apretude: New Drug to Prevent HIV Infection
Posted inInfections, New Drugs, Regulatory

Apretude: New Drug to Prevent HIV Infection

December 21, 2021September 8, 2022

Injecting cabotegravir once every two months will high effectively protect against HIV infection.

Fetroja/Fetcroja: New Cephalosporin That Bypasses All Antibiotic Resistance
Posted inInfections, New Drugs, Regulatory

Fetroja/Fetcroja: New Cephalosporin That Bypasses All Antibiotic Resistance

December 11, 2021September 8, 2022

The antibiotic Fetroja/Fetcroja penetrates bacteria like a Trojan horse.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News